Ironwood Pharmaceuticals (IRWD) Stock Analysis & AI Equity Report
Ironwood Pharmaceuticals (IRWD) overview
Ironwood Pharmaceuticals (IRWD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 296m and operating profit of USD 98.5m; the year-end share price was 3.37 USD and market capitalisation was USD 550m. Ironwood Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ironwood Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals develops and commercializes therapies for gastrointestinal and rare diseases. Its commercial product LINZESS (linaclotide) is used to treat specified forms of irritable bowel syndrome with constipation and chronic or functional constipation in adults and pediatric patients, with indications varying by market. The company works with pharmaceutical partners to develop and commercialize linaclotide internationally and is developing apraglutide for short bowel syndrome.
Generate the Ironwood Pharmaceuticals report
Ironwood Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ironwood Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ironwood Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.